Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 Capex-to-Operating-Income is 0.00 as of Jun. 2026. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.44 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 395 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 253164.3% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Xvivo Perfusion AB (OTCPK:XVIPF) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Xvivo Perfusion AB Capex-to-Operating-Income Related Terms
Xvivo Perfusion AB Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Capex-to-Operating-Income Chart
XVIPF vs ABT, SYK, MDT: Capex-to-Operating-Income Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Capex-to-Operating-Income vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.00 mean?
Xvivo Perfusion AB (XVIPF) has a Capex-to-Operating-Income of 0.00 as of Jun. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Xvivo Perfusion AB and its competitors. Over the past decade, Xvivo Perfusion AB's Capex-to-Operating-Income has ranged from 2.16 to 29.39. According to the industry distribution chart, Xvivo Perfusion AB ranks #999999 out of 395 companies in the Medical Devices & Instruments industry.
Is Xvivo Perfusion AB's Capex-to-Operating-Income too high?
Xvivo Perfusion AB's current Capex-to-Operating-Income is 0.00. Over the past 10 years, this metric has ranged from a low of 2.16 to a high of 29.39. Based on the distribution chart, Xvivo Perfusion AB ranks #999999 out of 395 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Capex-to-Operating-Income compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #999999 out of 395 companies for Capex-to-Operating-Income. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Capex-to-Operating-Income is 0.48. Historically, Xvivo Perfusion AB's own Capex-to-Operating-Income has ranged from 2.16 to 29.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Medical Devices & Instruments company?
The median Capex-to-Operating-Income among Medical Devices & Instruments companies is 0.48, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Capex-to-Operating-Income is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Capex-to-Operating-Income is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.44, compared to a current price of $24.50 — trading 44.9% below its estimated fair value. The current Capex-to-Operating-Income is 0.00. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Capex-to-Operating-Income is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $24.50 is trading 44.9% below its estimated GF Value™ of $44.44.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Capex-to-Operating-Income: 0.00
GF Value™: $44.44 vs. price of $24.50 (44.9% below fair value)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
